These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17455324)

  • 21. Adhesion forces in interactive mixtures for dry powder inhalers--evaluation of a new measuring method.
    Lohrmann M; Kappl M; Butt HJ; Urbanetz NA; Lippold BC
    Eur J Pharm Biopharm; 2007 Sep; 67(2):579-86. PubMed ID: 17418548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H; Markefka P; teWierik H; Kammelar R
    Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dry powder inhaler formulation.
    Telko MJ; Hickey AJ
    Respir Care; 2005 Sep; 50(9):1209-27. PubMed ID: 16122404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What is the role of particle morphology in pharmaceutical powder aerosols?
    Chan HK
    Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
    Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Force control and powder dispersibility of spray dried particles for inhalation.
    Weiler C; Egen M; Trunk M; Langguth P
    J Pharm Sci; 2010 Jan; 99(1):303-16. PubMed ID: 19533606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Entrainment of lactose inhalation powders: a study using laser diffraction.
    Watling CP; Elliott JA; Cameron RE
    Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of particle morphology on the triboelectrification in dry powder inhalers.
    Murtomaa M; Mellin V; Harjunen P; Lankinen T; Laine E; Lehto VP
    Int J Pharm; 2004 Sep; 282(1-2):107-14. PubMed ID: 15336386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers.
    Jones MD; Young P; Traini D
    Adv Drug Deliv Rev; 2012 Mar; 64(3):285-93. PubMed ID: 22265843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of budesonide nanocluster dry powder aerosols: preformulation.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3434-44. PubMed ID: 22623018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhalable tranexamic acid for haemoptysis treatment.
    Haghi M; van den Oetelaar W; Moir LM; Zhu B; Phillips G; Crapper J; Young PM; Traini D
    Eur J Pharm Biopharm; 2015 Jun; 93():311-9. PubMed ID: 25936858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH; Danède F; Descamps M; Flament MP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations.
    Mangal S; Meiser F; Tan G; Gengenbach T; Denman J; Rowles MR; Larson I; Morton DA
    Eur J Pharm Biopharm; 2015 Aug; 94():160-9. PubMed ID: 26007290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
    Pilcer G; Sebti T; Amighi K
    Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of budesonide nanocluster dry powder aerosols: formulation and stability.
    El-Gendy N; Huang S; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3445-55. PubMed ID: 22619045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
    Grasmeijer F; de Boer AH
    Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel alternative methods for the delivery of drugs for the treatment of asthma.
    Chan HK; Chew NY
    Adv Drug Deliv Rev; 2003 Jul; 55(7):793-805. PubMed ID: 12842601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of carrier on the performance of dry powder inhalers.
    Saint-Lorant G; Leterme P; Gayot A; Flament MP
    Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.